Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
Journal
Journal of Thoracic Oncology
Journal Volume
9
Journal Issue
8
Pages
1171-1179
Date Issued
2014
Author(s)
Abstract
Introduction: The prevalence, demographic features, and clinical outcomes of lung adenocarcinoma patients with novel ROS1 oncogenic rearrangement in East Asian populations are not clear. This study aimed to investigate the clinical and prognostic characteristics of lung adenocarcinoma in patients with ROS1 fusion compared with other driver mutations. Methods: Multiplex reverse transcription-polymerase chain reaction was used to detect the ROS1 fusion gene in lung adenocarcinoma cases. Immunohistochemistry was used to confirm the expression of ROS1. The demographic data and clinical outcomes of patients with the ROS1 fusion gene were compared with those of patients without the ROS1 fusion gene, including those with the EGFR mutation, EML4-ALK fusion, KRAS mutation, and quadruple-negative patients. Results: Of 492 patients with lung adenocarcinoma, 12 (2.4%) had the ROS1 fusion gene. Their median age was 45.0 years, significantly younger than that of the ROS1 fusion-negative cohorts (p <0.001). Acinar (including cribriform) and solid patterns were the two most common histologic subtypes in the ROS1 fusion tumors (7 of 12, 58.3%) and were predominantly seen in CD74-ROS1 fusion tumors (66.7%). There was no significant survival difference between the ROS1 fusion-positive and ROS1 fusion-negative cohorts in surgical group, but ROS1 fusion-positive patients might have worse outcomes than EGFR-mutant patients in the stage IV group. Conclusions: The ROS1 fusion gene can be successfully detected in East Asian patients with lung adenocarcinoma using multiplex reverse transcription-polymerase chain reaction. These patients tend to be younger and have characteristic histologic subtypes. Due to the small number of ROS1 fusion patients, the prognostic value of ROS1 fusion need further studies to confirm. Copyright ? 2014 by the International Association for the Study of Lung.
SDGs
Other Subjects
crizotinib; pemetrexed; B lymphocyte antigen; EGFR protein, human; EML4-ALK fusion protein, human; epidermal growth factor receptor; HLA antigen class 2; invariant chain; KRAS protein, human; oncoprotein; protein tyrosine kinase; Ras protein; ROS1 protein, human; SDC4 protein, human; SLC34A2 protein, human; sodium phosphate cotransporter 2b; syndecan 4; adult; aged; article; cancer patient; cancer prognosis; cd74 ros1 fusion gene; clinical feature; controlled study; female; fusion gene; gene expression; gene mutation; human; immunohistochemistry; lung adenocarcinoma; major clinical study; male; middle aged; multiplex polymerase chain reaction; population research; priority journal; prospective study; reverse transcription polymerase chain reaction; ROS1 gene; adenocarcinoma; age; Asian continental ancestry group; comparative study; disease free survival; genetics; Lung Neoplasms; mutation; pathology; prognosis; sex difference; survival rate; Taiwan; very elderly; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Asian Continental Ancestry Group; Disease-Free Survival; Female; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; ras Proteins; Receptor, Epidermal Growth Factor; Sex Factors; Sodium-Phosphate Cotransporter Proteins, Type IIb; Survival Rate; Syndecan-4; Taiwan
Publisher
Lippincott Williams and Wilkins
Type
journal article